

## SUBJECT INDEX

(Numbers cited are abstract numbers)

### A

Absolute lymphocyte count 444  
ABVD therapy 546  
ACVBP regimen 203  
Adhesion molecules 27, 135, 184, 318, 566  
Adjuvant therapy 112, 118, 274, 279, 365, 411, 507  
Adolescents 35, 85, 86, 90, 91, 324, 325, 326, 327  
Adult T-cell leukemia 511  
Aggressive lymphoma 19, 44, 67, 134, 196, 203, 208, 287, 306, 342, 347, 357, 399, 417, 426, 458, 462, 469, 472, 477, 481, 487, 489, 496, 497, 508, 519, 582  
AIDS 70, 299, 304, 305, 306, 344, 466, 523  
AIDS, lymphoma 70  
Alemtuzumab 19, 38, 39, 41, 177, 183, 294, 323, 327, 344, 520  
Alkylating agents 278, 322, 338, 423, 450, 522, 569  
Allogeneic blood stem cell transplantation 90  
Allogeneic bone marrow transplantation 39  
Allogeneic stem cell transplantation 6, 19, 43, 218, 392, 435, 518  
Allogeneic transplantation 211  
Allopurinol 96, 595  
Anaplastic large cell lymphoma 86, 116, 131, 154, 163, 342, 514, 519, 598  
Anaplastic lymphoma kinase 514  
Anaplastic morphology 600  
Anemia 23, 41, 96, 181, 221, 222, 223, 226, 267, 300, 319, 323, 386, 389, 390, 394, 405, 415, 416, 443, 450, 462, 467, 479, 480, 484, 488, 490, 527, 533, 541, 547, 548, 549, 569, 575, 587  
Angiogenesis 331, 362, 488, 524, 590  
Angiogenic factors 488  
Angioimmunoblastic T-cell lymphoma 81, 308, 322  
Animal models 8, 21, 22, 23, 31, 56, 101, 114, 132, 135, 138, 139, 141, 256, 313, 328, 330, 403, 580, 581, 583, 589, 592, 616  
Anthracyclines 53, 78, 214, 220, 223, 275, 287, 288, 290, 376, 377, 388, 403, 435, 468, 471, 491, 496, 497, 504, 513, 517, 551  
Antiangiogenic therapy 55, 111, 331, 553  
Antibody dependent cellular toxicity 397, 482  
Antibody response 17, 133  
Anti-CD20 antibody 53, 251, 390, 450  
Anti-CD20 monoclonal antibody 107, 402  
Anti-CD30 antibody 330  
Antiretroviral therapy 5, 70, 304, 523  
Anti-tumor immunity 132  
Apoptosis 1, 7, 10, 13, 22, 23, 26, 27, 37, 56, 96, 97, 105, 110, 111, 117, 119, 124, 125, 138, 149, 153, 157, 158, 167, 171, 172, 175, 178, 231, 232, 237, 313, 328, 337, 352, 361, 397, 428, 436, 457, 482, 526, 557, 575, 576, 581, 589, 590, 591, 592, 607, 611, 615, 617  
Arsenic trioxide 338  
Ascorbic acid 338  
ASCT 12, 54, 65, 66, 71, 72, 130, 199, 200, 212, 214, 215, 216, 217, 266, 305, 315, 321, 368, 369, 404, 430, 431, 450, 452, 454, 473, 490, 495, 500, 503, 505, 506, 510, 519, 552, 553, 593, 603  
Asthenia 332

ATM gene 169, 558  
ATM protein 178  
Autoantibodies 608, 617  
Autoimmune hemolytic anemia 49  
Autologous hematopoietic stem cell transplantation 33  
Autologous stem cell support 68, 211, 246, 496, 505  
Autologous stem cell transplantation 54, 65, 199, 213, 214, 246, 388, 452, 462, 477, 483, 494, 500, 504, 508, 552, 553, 578  
Autologous transplantation 6, 12, 14, 19, 33, 38, 43, 54, 62, 65, 68, 90, 112, 129, 177, 199, 211, 213, 214, 216, 218, 246, 254, 298, 318, 331, 369, 388, 393, 452, 454, 455, 462, 477, 483, 490, 493, 494, 496, 498, 500, 502, 504, 505, 508, 552, 553, 578, 593, 597, 603  
Aza-anthracenedione 403

### B

B symptoms 33, 72, 181, 202, 205, 221, 249, 262, 263, 264, 265, 285, 370, 376, 379, 414, 429, 431, 465, 472, 479, 480, 486, 513, 519, 531, 532, 540, 542, 552, 553, 554, 600  
b2-M 236  
b2-microglobulin 127, 391  
B-ALL 354  
Bax 110, 175, 178  
BBR 2778 583  
B-cell chronic lymphocytic leukemia 117, 172, 400, 561  
B-cell clonality 195  
B-cell differentiation 135, 231  
B-cell lymphoma 14, 27, 28, 30, 47, 102, 111, 120, 128, 144, 145, 147, 159, 201, 202, 223, 242, 310, 317, 324, 334, 350, 352, 356, 357, 362, 384, 390, 397, 399, 403, 405, 417, 473, 476, 490, 494, 496, 518, 587, 606  
B-cell malignancies 111, 129, 254, 329, 349, 354, 390  
B-cell neoplasia 144  
B-cell non-Hodgkin's lymphoma 207  
B-cell type 121  
Bcl-2 1, 24, 44, 47, 50, 66, 77, 103, 111, 119, 124, 126, 178, 206, 209, 218, 237, 241, 245, 247, 248, 363, 378, 382, 385, 394, 404, 436, 462, 465, 508, 589, 613  
BCL-2 expression 466  
BCL-6 24, 27, 108, 168, 209, 295, 361, 523, 525  
BCL-6 gene 295  
B-CLL 117, 172, 174, 176, 181, 184, 361, 384, 419, 458, 558, 559, 561, 564, 567, 569, 573, 588, 615  
BCNU 212, 298, 404, 448  
BEACOPP regimen 57, 266, 269, 277, 278, 279, 370, 373, 539, 541, 542, 547, 549  
BEAM regimen 473  
Bendamustine 101, 584  
Bexxar 453  
bFGF 575, 576  
Binet stage A 179, 361, 566  
Blastoid variants 151  
Bleomycin 203, 226, 304, 516, 518, 536, 541, 544, 547, 600  
Blood transfusion 443  
Blood transfusions 443  
Bone marrow 1, 8, 10, 20, 21, 27, 33, 37, 40, 49, 50, 62, 63, 64, 81, 89, 98, 106, 117, 132, 139, 140, 165, 168, 173, 176, 196, 200, 201, 204, 240, 248, 251, 255, 256, 259, 286, 319, 321, 324, 333, 350, 354, 360, 378, 379, 383, 385,

391, 410, 412, 429, 435, 444, 445, 453, 462, 465, 467, 472, 474, 479, 481, 485, 486, 490, 499, 508, 515, 532, 535, 574, 576, 588, 596, 613  
Bone marrow, biopsy 286, 379, 532  
Bone marrow, involvement 27, 63, 81, 200, 255, 324, 378, 453, 472, 474, 479, 485, 486, 490  
Bone marrow, transplantation 33  
Bone pain 570  
Breast cancer 1, 32, 272, 273, 577  
Breast cancer, risk 32  
Burkitt translocation 120  
Burkitt's lymphoma 7, 51, 129, 354, 399, 415

### C

CA 125 484  
Campath-1H 19, 41, 321  
CAMPATH-1H 19, 41, 321, 323, 344  
Cancer risk 3  
Carboplatin 488, 497  
Cardiac toxicity 257, 403, 405, 475, 499, 509  
Case-control study 4, 154, 238, 310  
Caspase 3 119, 436, 592  
Caspase 3, activation 592  
CCI-779 95, 101  
CD10 expression 81, 245, 523  
CD15 262, 530  
CD20 14, 49, 77, 83, 105, 114, 115, 126, 135, 139, 140, 151, 180, 183, 195, 198, 210, 215, 228, 239, 251, 255, 259, 262, 294, 318, 325, 334, 336, 384, 390, 397, 399, 402, 411, 428, 453, 482, 502, 505, 507, 523, 530, 545, 570, 571, 592, 594, 599, 614  
CD20 antigen 14, 397  
CD20 expression 140, 402, 523, 530, 545, 570, 592  
CD20+ 77, 83, 114, 180, 210, 215, 228, 259, 262, 325, 334, 336, 399, 411, 428, 453, 502, 505, 507  
CD23 37, 38, 49, 101, 126, 135, 151, 384, 411, 444, 530, 560, 563, 588  
CD3 27, 36, 37, 82, 89, 90, 126, 130, 131, 151, 156, 393, 515, 523  
CD30 33, 101, 116, 131, 154, 158, 312, 314, 330, 344, 415, 512, 514, 518, 545  
CD30 expression 154, 312, 314, 514  
CD30+ cell line 330  
CD34+ cells 212, 551, 610  
CD38 37, 38, 184, 257, 523, 530, 561, 562, 564, 565  
CD38 expression 561, 562, 565  
CD40 13, 37, 97, 128, 545  
CD5+ 37, 83, 444, 446  
CD80 101, 115, 585  
cDNA arrays 417  
Ceftriaxone 618  
Cell cultures 111, 161  
Cell cycle 53, 55, 56, 122, 149, 150, 157, 158, 175, 176, 178, 231, 337, 436, 457, 588  
Cell cycle regulators 149  
Cell development 21, 148  
Cell lines 10, 26, 29, 51, 110, 111, 128, 129, 135, 138, 139, 143, 145, 148, 149, 157, 158, 159, 160, 161, 163, 164, 178, 186, 240, 311, 312, 318, 330, 337, 349, 351, 358, 384, 390, 439, 447, 457, 511, 574, 576, 581, 588, 590, 592, 593, 607, 611, 614, 616  
Cellular interactions 111  
Central nervous system 35, 79, 91, 93, 105, 201, 202, 291, 297, 298, 299, 305, 315, 339, 414, 439, 440, 442, 445, 459, 593, 596, 598

- CGH 25, 48, 52, 123, 152, 157, 173, 230, 232, 291, 292, 437, 447
- Chemoimmunotherapy 39, 43, 294, 455
- Chemokine 16, 37, 136, 155, 176, 196, 439, 512, 574
- Chemokine, receptors 136, 439, 512, 574
- Chemo-radiation therapy 274, 538
- Chemoradiotherapy 203, 468, 469
- Chemosensitivity 214, 285, 305, 490
- Chemotherapy 6, 12, 14, 15, 16, 17, 18, 26, 32, 33, 34, 39, 41, 43, 44, 45, 49, 54, 55, 57, 58, 59, 60, 63, 64, 65, 68, 70, 73, 74, 76, 78, 79, 80, 90, 101, 102, 107, 108, 110, 111, 112, 116, 118, 119, 128, 133, 189, 190, 192, 198, 199, 203, 204, 207, 214, 216, 228, 229, 235, 239, 242, 243, 246, 249, 251, 252, 253, 254, 255, 256, 262, 263, 264, 265, 266, 269, 270, 271, 272, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 287, 288, 290, 294, 296, 297, 298, 299, 301, 304, 305, 312, 315, 316, 317, 322, 329, 331, 334, 338, 340, 348, 354, 363, 365, 368, 370, 371, 372, 373, 377, 386, 387, 388, 389, 390, 393, 394, 395, 396, 397, 398, 400, 406, 411, 413, 420, 424, 425, 427, 429, 430, 431, 432, 433, 434, 435, 440, 444, 445, 448, 449, 452, 453, 454, 456, 462, 464, 466, 468, 469, 470, 471, 472, 473, 474, 476, 479, 480, 482, 483, 484, 485, 487, 488, 492, 495, 498, 499, 501, 502, 504, 505, 506, 507, 510, 513, 517, 519, 521, 529, 531, 532, 534, 537, 539, 540, 541, 543, 544, 545, 546, 548, 549, 550, 551, 552, 553, 556, 571, 572, 577, 582, 584, 591, 592, 595, 596, 597, 598, 599, 600, 601, 603, 610, 613, 617
- Chlorambucil 60, 74, 338, 344, 376, 388, 390, 410, 450, 474, 571
- CHOP regimen 44, 45, 53, 55, 61, 64, 67, 70, 71, 73, 107, 108, 109, 140, 192, 200, 203, 208, 209, 212, 213, 217, 220, 223, 224, 225, 226, 227, 228, 250, 251, 252, 253, 288, 315, 320, 321, 323, 340, 363, 376, 388, 390, 394, 397, 398, 414, 424, 425, 426, 430, 432, 434, 440, 454, 465, 466, 467, 468, 469, 471, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 489, 497, 498, 501, 503, 505, 516, 517, 521, 571, 583, 587, 604, 613
- CHOP therapy 140, 224, 321, 363, 425, 479
- Chromosomal translocation 8, 51, 53, 56, 120, 145, 160, 167, 350, 354, 357, 358, 590
- Chromosomal, aberrations 48, 92, 120, 191, 232, 292, 356
- Chromosomal, abnormalities 77, 358, 411, 564
- Chromosomal, instability 157
- Chromosomal, translocations 51, 56, 120, 160, 167, 350, 357, 590
- Chronic lymphocytic leukemia 43, 148, 170, 173, 178, 254, 262, 294, 338, 344, 348, 386, 555, 557, 563, 565, 567
- Cidofovir 290
- Circulating lymphoma cells 502
- Cisplatin 212, 322, 489, 490, 505, 507, 516, 550
- Cis-platinum 229
- Cladribine 406, 407, 408, 573
- Clinical guidelines 32, 376
- Clinical research 481
- Clinical trials I, 11, 17, 18, 23, 24, 35, 61, 75, 101, 109, 114, 115, 129, 205, 216, 221, 222, 266, 277, 330, 337, 381, 386, 394, 476, 505, 580, 591, 592, 594
- Clinical trials, design 213
- Clinical, evolution 37, 167
- Clinical, management 125
- Clinical, outcome 6, 17, 24, 43, 54, 119, 142, 149, 151, 175, 205, 206, 237, 248, 283, 323, 329, 388, 398, 414, 526, 534, 600, 603
- Clinical, stage 40, 94, 202, 278, 312, 316, 474, 528, 534, 535, 537, 540, 541, 547, 600, 602
- Clonal, evolution 378
- CMF regimen 1
- Colon cancer 577
- Combination chemotherapy 27, 250, 253, 301, 316, 394, 465, 474, 500, 550
- Combination treatment 1, 6, 10, 12, 13, 27, 39, 44, 48, 53, 55, 56, 60, 63, 76, 83, 100, 101, 103, 104, 105, 107, 109, 115, 148, 149, 171, 179, 183, 190, 192, 198, 218, 227, 239, 250, 251, 253, 257, 258, 261, 279, 297, 299, 301, 302, 316, 320, 321, 322, 338, 340, 343, 344, 365, 380, 386, 389, 390, 394, 397, 398, 400, 405, 406, 407, 408, 413, 421, 433, 441, 447, 449, 450, 453, 457, 461, 465, 474, 475, 477, 480, 483, 489, 491, 494, 495, 500, 502, 508, 522, 536, 550, 551, 553, 567, 569, 570, 572, 573, 584, 585, 591, 592, 599, 610, 618
- Combined immuno-chemotherapy 53, 250, 251, 252, 253, 449
- Combined modality treatment 272, 275, 431, 441, 534, 540
- Complete response 60, 66, 68, 72, 80, 100, 105, 106, 116, 197, 198, 223, 226, 228, 241, 247, 251, 255, 262, 296, 297, 322, 340, 363, 386, 389, 390, 394, 397, 399, 400, 405, 411, 426, 432, 433, 442, 469, 476, 478, 484, 486, 488, 491, 494, 507, 519, 520, 522, 542, 568, 597, 617
- Computed tomography 19, 66, 114, 128, 204, 223, 243, 264, 266, 272, 274, 275, 281, 283, 284, 285, 286, 289, 298, 299, 304, 315, 332, 344, 367, 369, 370, 371, 372, 373, 430, 438, 471, 481, 485, 503, 509, 521, 532, 536, 537, 542, 553, 597, 600, 603, 613
- Concurrent therapy 247, 429, 568, 593
- Continuous infusion 11, 582, 610
- Conventional chemotherapy 12, 19, 53, 68, 72, 149, 199, 246, 322, 388, 398, 454, 472, 498, 550, 578, 617
- Conventional cytogenetic analysis 187, 358
- COP regimen 397
- Cost-effectiveness 498
- COX-2 331
- Creatinine level 339
- Cutaneous involvement 521
- Cutaneous T-cell lymphoma 47, 100, 311, 322, 512, 518, 520
- Cyclin dependant kinases 149, 337
- Cyclin, D1 8, 51, 52, 53, 55, 83, 95, 101, 126, 149, 150, 178, 186, 384, 444, 446, 450, 457
- Cyclophosphamide 1, 39, 40, 42, 53, 62, 66, 69, 76, 90, 108, 198, 203, 210, 211, 212, 217, 218, 224, 226, 228, 246, 249, 252, 258, 267, 301, 304, 323, 331, 344, 386, 388, 389, 390, 391, 404, 405, 406, 448, 449, 454, 456, 471, 473, 475, 476, 478, 485, 486, 487, 500, 501, 504, 505, 507, 517, 541, 547, 567, 571, 572, 573, 582
- Cytarabine 90, 149, 201, 203, 212, 298, 322, 489, 492, 494, 502, 504, 505
- Cytogenetic 1, 11, 12, 40, 46, 49, 50, 52, 77, 92, 120, 147, 148, 152, 173, 174, 186, 230, 232, 235, 292, 337, 357, 358, 359, 360, 377, 436, 444, 446, 450, 511, 515, 525, 558, 559, 561
- Cytogenetic, aberrations 446
- Cytogenetic, abnormalities 11, 49, 235, 515
- Cytogenetic, analysis 358, 359, 360, 377, 558
- Cytokines 16, 27, 97, 117, 134, 136, 155, 157, 163, 318, 575, 588
- Cytological grade 378
- Cytoreduction 212, 329
- Cytotoxic T-cells (CTL) 112, 344, 615
- Cytotoxicity 13, 39, 104, 394, 397, 482
- ## D
- Dacarbazine 516, 518, 544
- Death 10, 16, 22, 62, 88, 110, 136, 137, 193, 207, 213, 217, 223, 313, 322, 328, 331, 341, 349, 369, 374, 383, 405, 431, 444, 452, 465, 469, 476, 478, 486, 487, 498, 504, 513, 531, 543, 552, 565, 567, 569, 576, 587, 607, 618
- Decision making 370
- Dendritic cells 16, 17, 18, 27, 82, 132, 615
- Developing countries 2, 32, 413
- Dexamethasone 12, 13, 269, 489, 492, 505, 506, 579
- DHAP regimen 53, 489
- Differentiation 7, 26, 75, 111, 139, 141, 163, 168, 174, 358, 409, 436, 457, 523, 575
- Diffuse large B-cell lymphoma 8, 16, 25, 27, 28, 73, 75, 78, 86, 87, 92, 108, 121, 135, 143, 157, 185, 191, 193, 220, 227, 236, 242, 254, 256, 259, 288, 295, 307, 337, 350, 358, 362, 364, 383, 397, 415, 417, 419, 424, 425, 426, 430, 435, 458, 460, 464, 471, 473, 474, 475, 478, 485, 492, 494, 496, 507, 592, 610
- Diffuse large cell lymphoma 1, 30, 68, 70, 102, 155, 206, 207, 217, 399, 413, 422, 434
- Disease progression 17, 113, 118, 140, 176, 233, 256, 308, 368, 380, 386, 404, 430, 448, 453, 478, 517, 524, 534, 557, 584, 593, 598
- DNA 9, 10, 11, 13, 16, 17, 25, 27, 48, 51, 125, 137, 138, 140, 159, 167, 171, 173, 186, 187, 230, 232, 234, 248, 254, 295, 302, 303, 308, 313, 351, 356, 382, 384, 458, 464, 528, 561, 590, 609, 616
- DNA, methylation 351
- DNA, repair 13, 27
- Dose dense chemotherapy 479, 485
- Dose escalation 41, 67, 105, 106, 112, 393
- Dose intensification 370, 467
- Dose intensity 11, 67, 108, 224, 228, 265, 370, 467, 471, 485, 487, 546, 548, 582
- Dose ranging 385, 534
- Doxorubicin 58, 108, 203, 204, 224, 226, 228, 246, 276, 323, 432, 448, 454, 473, 475, 476, 478, 481, 485, 486, 501, 516, 517, 518, 541, 544, 547, 581, 583, 586, 600
- Drug resistance 13, 125, 312, 557
- Durable remission 14, 42, 247, 256, 266, 368, 407, 423, 430, 568
- ## E
- EBV-DNA 162
- Education 32, 238, 604
- Elderly patients 34, 44, 45, 53, 64, 65, 221, 222, 227, 228, 229, 322, 388, 425, 441, 442, 469, 474, 475, 476, 487, 509, 541, 547, 567, 586, 587
- Epidemiological study 341
- Epirubicin 304, 506, 507, 582
- EPOCH 79, 108, 472, 481, 582
- Epoetin alfa 443
- Epoetin beta 541, 547, 612
- Epratuzumab 106, 380
- Epstein-Barr virus 7, 261, 290, 307, 308, 309, 310, 345, 349, 525, 528, 529, 596
- Erythropoietin 443, 549, 612
- ESHAP 322, 473, 477, 490, 494, 503, 593
- Estrogen 279
- Etoposide 11, 66, 67, 90, 108, 119, 171, 212, 217, 226, 267, 283, 400, 467, 474, 481, 487, 488, 490, 497, 500, 504, 505, 507, 516, 541, 547, 610
- Event-free survival 12, 68, 69, 72, 203, 241, 246, 258, 287, 322, 362, 415, 416, 441, 450, 469, 476, 478, 507, 528, 545

Expression profiles 29, 120, 124, 125, 149, 166, 463, 523  
 Extranodal involvement 202, 203, 304, 395, 469, 472, 483  
 Extranodal lymphoma 143, 303, 427, 434, 438  
 Extranodal NK-cell lymphoma 316

## F

Family history 562  
 FAMP 401  
 Fas 138, 232, 313  
 Fas-mediated apoptosis 138  
 FCR 39, 198, 218  
 Fertility 278, 279, 554  
 Field radiotherapy 203, 204, 366, 469, 536  
 Filgrastim 254  
 First relapse 14, 33, 233, 323, 489, 493, 593  
 First remission 14, 15, 17, 72, 199, 267, 505  
 First-line therapy 14, 65, 179, 239, 302, 326, 406, 462, 483, 583, 618  
 FISH 9, 24, 40, 42, 48, 51, 52, 77, 83, 84, 120, 143, 145, 147, 152, 159, 160, 166, 171, 173, 187, 233, 235, 245, 291, 292, 357, 359, 360, 374, 436, 437, 446, 447, 450, 511, 515, 558, 564  
 FISH analysis 9, 40, 83, 145, 171, 235, 359, 360, 446, 511, 558  
 Flavopiridol 96  
 Flow cytometry 36, 39, 40, 42, 89, 110, 130, 140, 149, 172, 176, 182, 184, 239, 294, 318, 361, 410, 456, 563, 565, 574, 592  
 Fludarabine 19, 39, 40, 41, 42, 53, 63, 101, 171, 183, 198, 211, 218, 252, 258, 323, 344, 386, 387, 389, 390, 391, 403, 405, 449, 456, 510, 567, 571, 573, 591, 610, 613  
 Folinic acid 197, 441  
 Follicle center lymphoma 47  
 Follicular dendritic cells 24, 135, 524  
 Follicular lymphoma 1, 14, 15, 16, 17, 24, 26, 29, 59, 60, 61, 63, 65, 76, 77, 94, 104, 109, 118, 137, 143, 145, 148, 155, 160, 211, 218, 231, 233, 235, 239, 240, 241, 242, 243, 244, 245, 246, 247, 249, 251, 252, 253, 254, 256, 259, 334, 335, 350, 356, 368, 374, 375, 376, 378, 379, 381, 382, 383, 384, 385, 386, 388, 389, 390, 394, 399, 404, 407, 408, 415, 419, 427, 435, 449, 453, 473, 476, 480, 582, 592, 610  
 Follicular lymphoma, advanced stage 388  
 Follicular non-Hodgkin's lymphoma 114  
 Front-line therapy 90, 201

## G

Gastric cancer 577  
 Gastric MALT lymphoma 74, 191, 193, 421, 423, 429  
 Gastrointestinal tract 102, 420, 427, 499, 596  
 G-CSF 108, 197, 212, 215, 226, 254, 265, 333, 394, 402, 467, 473, 479, 480, 484, 485, 491, 506, 509, 539, 575, 578, 603, 610  
 Gemcitabine 100, 495, 496, 551  
 GEMOX regimen 496  
 Genasense 101, 103  
 Gene expression 7, 9, 16, 26, 27, 28, 29, 46, 48, 49, 52, 87, 105, 120, 122, 124, 125, 136, 137, 142, 146, 150, 155, 166, 167, 173, 196, 205, 214, 230, 239, 291, 335, 340, 349, 351, 357, 384, 409, 417, 436, 447, 463, 464, 581, 590, 591  
 Gene rearrangements 49, 121, 153, 154, 182, 195, 306, 421, 555, 609  
 Gene, amplification 25, 56, 77, 590

Gene, expression profiling 26, 27, 29, 46, 48, 52, 120, 122, 136, 137, 142, 196, 205, 230, 239, 349, 357, 447, 464, 581, 591  
 Genetic polymorphism 134  
 Genetic, analysis 261, 437, 444, 609  
 Genetic, polymorphisms 134  
 Genomic, aberrations 36, 120, 145, 178, 232  
 Germinal center 8, 21, 24, 26, 30, 52, 56, 87, 108, 146, 155, 161, 257, 295, 357, 378, 411, 435, 506, 523  
 Germinal center, lymphomas 21  
 GM-CSF 104, 118, 570, 580  
 Graft-versus-host disease 19, 510  
 Graft-versus-lymphoma effect 19  
 Granulocyte colony-stimulating factor 476  
 Growth factors 165, 224, 265, 333, 460, 488, 524, 546, 548, 566, 576

## H

Hairy cell, leukemia 181, 341  
 HD9 trial 542  
 Heat shock proteins 591, 607  
*Helicobacter pylori* 74, 193, 194, 302, 418, 421, 423, 425, 427  
 Hematological, malignancies 582  
 Hematological, toxicity 40, 425, 456, 475, 485, 494, 540, 551, 567  
 Hematopoiesis 169  
 Hemoglobin 39, 63, 181, 222, 224, 249, 258, 264, 329, 374, 381, 443, 533, 549, 612  
 Hemophagocytic syndrome 435  
 Hepatic toxicity 207, 228  
 Hepatitis C 6, 207, 238, 302, 343, 347  
 Herpes virus 307, 466  
 High dose chemotherapy 14, 33, 68, 216, 246, 263, 304, 321, 369, 388, 494, 498, 500, 504, 506, 508, 552, 578  
 High grade B-cell lymphoma 120  
 High risk International Prognostic Index 473  
 High risk patients 44, 68, 73, 405, 414, 510  
 High tumor burden 246  
 High-dose chemotherapy 14, 33, 68, 216, 246, 263, 304, 321, 369, 388, 494, 498, 500, 504, 506, 508, 552, 578  
 High-dose cyclophosphamide 219  
 High-dose cytarabine 550  
 High-dose methotrexate 297, 299, 440, 441, 442, 443, 445  
 High-dose sequential therapy 501  
 High-dose therapy 14, 15, 19, 24, 64, 67, 200, 204, 211, 246, 254, 256, 368, 383, 404, 431, 450, 452, 454, 472, 477, 496, 498, 507, 578  
 Highly active anti-retroviral therapy 290  
 Histological, subtypes 6, 71, 359, 379, 399, 438, 496, 534, 535  
 Histological, transformation 362, 402  
 Histone deacetylase inhibitor 13, 101  
 HIV infection 201, 304, 306, 593  
 HLA antigens 42, 82, 112, 125, 127, 162, 211, 261, 291, 311, 328, 510, 515, 530, 615  
 Hodgkin's disease 7, 30, 32, 155, 260, 263, 304, 305, 343, 371, 524, 534, 537, 550, 551, 600, 602, 606, 610  
 Hodgkin's lymphoma 1, 5, 6, 29, 34, 51, 58, 59, 88, 101, 116, 143, 155, 158, 160, 161, 162, 164, 196, 204, 219, 222, 226, 238, 261, 263, 264, 265, 266, 268, 269, 270, 271, 272, 273, 274, 275, 277, 279, 280, 281, 282, 283, 285, 326, 331, 343, 345, 347, 359, 368, 369, 372, 373, 434, 462, 476, 500, 510, 524, 525, 528, 529, 531, 532, 536, 540, 541, 542, 543, 544, 545, 547, 549, 553, 554, 586, 590, 593, 603, 606, 607, 611  
 HRQOL 604

Hypercalcemia 94  
 Hyperfractionated radiotherapy 298  
 Hypoalbuminemia 533

## I

ICAM-1 135, 318, 566  
 Id genes 17  
 Idarubicin 229  
 Idiotype vaccine 17, 55, 132  
 Ifosfamide 90, 203, 300, 488, 491, 494, 497, 503, 516, 551, 610  
 Ig genes 56, 364  
 IgH genes 382  
 IgV genes 153  
 IL-10 134  
 IL-2 136, 407  
 Imatinib mesylate 125  
 Immune response 16, 17, 26, 118, 134, 135, 136, 312, 615  
 Immune system 18, 393, 617  
 Immunization 21, 118  
 Immunochemotherapy 60, 427  
 Immunocompromised patient 441  
 Immunocytochemistry 121  
 Immunocytoma 60, 244, 250, 386  
 Immunoglobulin genes 174  
 Immunohistochemical analysis 125  
 Immunohistochemistry 28, 46, 83, 87, 109, 110, 122, 125, 156, 158, 161, 163, 164, 195, 209, 237, 245, 291, 309, 327, 345, 346, 357, 374, 439, 524, 529, 607  
 Immunophenotypic heterogeneity 515  
 Immunophenotyping 1, 24, 38, 48, 77, 397, 422, 515  
 Immunostaining 307, 411, 512  
 Immunosuppression 4, 14, 162, 254, 393  
 Immunotherapy 14, 16, 17, 18, 55, 112, 167, 170, 177, 239, 252, 294, 327, 329, 332, 389, 390, 393, 404, 512, 615  
 Indolent lymphoma 19, 94, 104, 210, 247, 250, 252, 336, 399, 408, 462, 474, 478, 490, 573  
 Indolent lymphoma, advanced stage 388  
 Indolent non-Hodgkin's lymphoma 63, 386  
 Infection 6, 41, 65, 69, 74, 96, 113, 207, 215, 257, 258, 290, 302, 303, 305, 307, 308, 309, 310, 343, 344, 345, 346, 347, 349, 387, 390, 391, 392, 401, 421, 424, 425, 427, 429, 442, 450, 467, 475, 486, 496, 520, 525, 541, 542, 546, 548, 555, 596, 602, 610  
 Infectious complications 392, 475, 567  
 Influenza 113, 133  
 Informed consent 140, 142, 180, 193, 213, 273, 579  
 Intensified induction 11, 53, 71  
 Intention-to-treat analysis 73  
 Interferon alpha 6, 11, 53, 54, 76, 79, 124, 136, 157, 162, 246, 247, 253, 343, 355, 388, 395, 396, 408  
 Interleukin-1 134, 136, 155, 333, 355, 576  
 Interleukin-10 134, 409  
 Interleukin-11 155, 333  
 Interleukin-2 136, 407  
 Interleukin-4 128, 588  
 Interleukin-6 97, 167, 409, 575, 576  
 International Prognostic Index 24, 58, 63, 68, 70, 72, 73, 76, 78, 80, 102, 107, 108, 109, 119, 121, 122, 127, 130, 151, 196, 199, 204, 205, 206, 209, 211, 213, 217, 223, 225, 226, 228, 229, 236, 241, 249, 250, 286, 287, 288, 290, 320, 322, 323, 331, 342, 350, 362, 370, 376, 377, 380, 387, 388, 397, 408, 412, 414, 415, 416, 426, 430, 431, 435, 438, 445, 460, 461, 465, 466, 467, 472, 473, 474, 475, 477, 478, 479, 480, 481, 482, 483, 485, 486, 497, 498,

501, 502, 503, 506, 507, 513, 516, 519, 534, 586, 587

International Prognostic Index, age adjusted 203, 476, 498, 523

Intrathecal chemotherapy 90, 91, 105, 298, 441, 445, 459

Involved field radiotherapy 204, 366, 385, 534

IPI score 58, 70, 76, 80, 107, 122, 151, 205, 211, 228, 229, 250, 320, 388, 397, 431, 472, 477, 479, 481, 482, 503, 516, 534, 586, 587

## K

Keyhole limpet hemocyanin 580

## L

Large B-cell lymphoma 24, 47, 317, 364, 422, 471, 492, 494, 606

Laser microdissection 314

Late toxicity 265, 391, 543

LD-PCR 354, 437

Leukemia 1, 14, 23, 36, 49, 57, 61, 69, 84, 86, 89, 101, 149, 162, 167, 170, 172, 174, 180, 181, 183, 197, 210, 211, 271, 294, 310, 312, 316, 337, 338, 344, 348, 351, 354, 359, 389, 390, 515, 536, 543, 555, 556, 558, 560, 571, 590, 598, 599, 600, 613, 616

Leukemia, acute lymphoblastic 89, 93, 108, 211, 342, 348, 354, 512, 599

Leukemia, acute myeloid 1, 274, 283, 402, 536, 615

Leukemia, acute promyelocytic 338

Leukemia, chronic lymphocytic 36, 37, 38, 39, 40, 41, 42, 43, 49, 96, 99, 101, 111, 117, 143, 148, 165, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 242, 254, 262, 294, 310, 337, 338, 344, 348, 361, 384, 386, 389, 390, 392, 400, 419, 458, 510, 555, 556, 557, 558, 559, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 573, 588, 589, 591, 615

Leukemia, chronic myelogenous 51, 615

Leukopenia 34, 300, 389, 390, 401, 442, 541

Liposomal doxorubicin 228, 586

Long-term follow-up 32, 62, 256, 276

Long-term survival 57, 132, 490, 542, 601

Long-term toxicity 213

Low dose involved field radiotherapy 242

Low grade MALT lymphoma 418

Lung cancer 32, 450, 577

Lymph nodes 33, 81, 118, 137, 140, 161, 183, 351, 360, 378, 412, 428, 468, 527, 596

Lymphoblastic lymphoma 86, 89, 124, 434, 521, 595, 599

Lymphoid malignancies 3, 95, 96, 125, 351, 400, 605

Lymphoma diagnosis 75

Lymphoma subgroup 462

Lymphoma survival 14

Lymphoma, aggressive 19, 44, 67, 134, 196, 203, 208, 287, 306, 342, 347, 357, 399, 417, 426, 458, 462, 469, 472, 477, 481, 487, 489, 496, 497, 508, 519, 582

Lymphoma, Burkitt's 7, 51, 129, 354, 399, 415

Lymphomagenesis 135, 306, 335, 347, 356, 384

Lymphomatous meningitis 105

Lymphopenia 99, 130, 254, 257, 344, 407, 513, 533, 534

Lymphoplasmacytic lymphoma 50, 94, 168, 250, 555, 572

Lymphoproliferative disorders 131, 153, 154, 183, 258, 307, 344, 359, 392, 568

## M

Mabthera 398, 402

Magnetic resonance imaging 219, 296

Malignant lymphoma 1, 53, 134, 140, 211, 239, 280, 312, 347, 351, 362, 365, 411, 440, 460, 552, 606, 611, 617

Malignant plasma cells 141, 574

MALT 50, 74, 94, 103, 139, 143, 187, 188, 191, 192, 193, 194, 195, 259, 301, 302, 303, 324, 379, 397, 411, 412, 415, 417, 418, 419, 420, 421, 422, 423, 424, 427, 428, 429, 436, 437, 474

MALT lymphoma 143, 187, 188, 191, 192, 194, 301, 302, 303, 412, 418, 419, 420, 422, 427, 428, 437, 474

MALT lymphoma of the stomach 187

Mantle cell lymphoma 49, 51, 53, 54, 55, 60, 77, 84, 95, 101, 118, 128, 143, 148, 149, 150, 151, 152, 160, 180, 196, 198, 199, 211, 242, 244, 252, 253, 254, 256, 259, 332, 337, 338, 340, 360, 368, 384, 388, 389, 390, 399, 400, 401, 444, 446, 447, 448, 449, 450, 452, 454, 457, 573, 581, 582, 611

Marginal zone B cells 139

Marginal zone B-cell lymphoma 195, 358, 415, 419, 429

Marginal zone lymphoma 49, 50, 77, 99, 143, 195, 242, 259, 292, 317, 380, 395, 399, 411, 420, 555

Matrix-CGH 120, 157

MDR-1 582

Melanoma 577

Melphalan 10, 11, 12, 13, 19, 200, 212, 214, 217, 448, 499, 501, 504, 551, 578

Membrane protein 7, 135, 138, 261, 311, 529, 600

Mesna 197, 488, 503

Meta-analysis 68, 166, 274, 612

Methotrexate 69, 203, 218, 267, 296, 298, 344, 414, 448, 500, 505, 513

MGUS 8, 139, 167

MIB-1 87, 418

Microarray analysis 108, 163

Microarrays 9, 13, 87, 108, 109, 120, 122, 125, 137, 142, 145, 150, 155, 156, 163, 173, 384, 436, 447, 464

Microsatellites 154, 314

Microvessel density 362, 524

Minimal residual disease 40, 42, 89, 177, 194, 283, 326, 354, 367, 382, 383, 393, 508

Mitoxantrone 40, 53, 66, 171, 217, 226, 252, 387, 388, 391, 403, 449, 491, 501, 504, 506, 571, 583, 616

Molecular remission 177, 247, 248, 251, 404, 421

Monoclonal antibodies 1, 15, 38, 42, 45, 46, 52, 54, 101, 110, 115, 116, 131, 135, 139, 151, 161, 183, 309, 311, 318, 328, 355, 397, 465, 478, 486, 494, 512, 520, 527, 571, 585, 613

Monoclonal gammopathy 6, 50, 167, 608

Mononuclear cells 89, 170, 318

MOPP regimen 1

Mucositis 265, 389, 390, 405, 472, 475, 479

Multidrug resistance 582

Multiple myeloma 8, 12, 20, 21, 51, 101, 139, 141, 165, 166, 336, 337, 419, 574, 575, 577, 578, 579, 593, 611

Myc 77

Mycosis fungoides 100, 131, 311, 313, 520, 522

Myeloablative therapy 15, 54

Myelodysplastic syndromes 552

Myeloma cells 575, 591

Myelosuppression 101, 218, 228, 297, 442, 484, 488, 586

MZL 49, 50, 77, 143, 183, 223, 259, 292, 294, 317, 336, 411, 420, 509, 555, 568

## N

Neurotoxicity 298, 441, 548, 553, 584, 587

Neutropenia 40, 41, 65, 96, 98, 103, 108, 115, 220, 223, 224, 228, 247, 254, 257, 319, 321, 335, 340, 386, 387, 391, 394, 400, 401, 403, 405, 450, 470, 472, 475, 476, 479, 480, 484, 485, 486, 488, 490, 491, 496, 517, 539, 544, 546, 548, 550, 553, 567, 568, 569, 570, 579, 584, 587, 593, 594, 610, 618

NK cells 82, 136, 318, 328, 355, 515

Nodular sclerosis 155, 164, 268, 345, 369, 526, 528, 529, 530, 535, 600

Non-Hodgkin's lymphoma 1, 2, 5, 6, 19, 29, 35, 46, 51, 59, 60, 61, 63, 67, 68, 69, 70, 72, 77, 85, 86, 88, 91, 92, 99, 101, 103, 105, 106, 107, 109, 112, 115, 118, 123, 127, 129, 133, 135, 141, 142, 143, 150, 160, 189, 192, 198, 204, 206, 207, 208, 211, 212, 213, 215, 216, 217, 218, 219, 220, 221, 222, 226, 228, 231, 235, 238, 241, 251, 255, 259, 276, 280, 288, 295, 298, 299, 305, 306, 317, 324, 325, 327, 328, 329, 330, 331, 333, 334, 336, 342, 343, 346, 347, 350, 353, 355, 356, 357, 359, 362, 367, 368, 379, 380, 384, 385, 386, 389, 390, 392, 395, 396, 397, 398, 400, 401, 402, 403, 412, 413, 415, 416, 419, 420, 427, 434, 438, 440, 443, 448, 458, 459, 461, 462, 464, 465, 467, 472, 474, 476, 477, 479, 480, 482, 484, 487, 488, 489, 493, 495, 498, 499, 500, 502, 505, 508, 509, 510, 513, 521, 532, 550, 555, 567, 568, 573, 583, 585, 586, 587, 590, 591, 593, 595, 596, 599, 604, 605, 606, 611, 613, 618, 619

Notch2 20

Nucleotide polymorphism 234

## O

Ocular adnexa 191, 301

Oncogenes 8, 21, 56, 145, 157, 186, 346, 351, 354, 356, 357, 611

Outcome prediction 46

Outpatient 41, 106, 115, 273, 338, 501, 539, 567, 593, 603, 604

Oxaliplatin 492, 496

Oxidative damage 556

## P

p21 10, 178, 350, 511

p27 122, 175, 178

p53 8, 10, 22, 52, 56, 96, 152, 171, 178, 378, 436, 446, 527, 558, 559

p53 gene 527, 558, 559

p53 protein expression 178

Paclitaxel 220, 494

Pain 269, 336, 432, 434, 497, 596

PARP 592

Patient outcome 87, 109

Patients 11, 14, 38, 59, 96, 99, 102, 165, 189, 192, 194, 197, 206, 260, 264, 280, 294, 366, 367, 420, 434, 457, 463, 532, 604, 605

PCR analysis 166, 168, 248, 311, 385, 421

PCR negativity 39, 394

Pediatric patients 87

Pegfilgrastim 41, 485, 546, 548

Pentostatin 410, 572

Peripheral blood 29, 49, 66, 69, 81, 89, 112, 129, 130, 136, 140, 170, 176, 183, 200, 210, 211, 248, 251, 261, 267, 318, 335, 355, 360, 385,

- 391, 394, 429, 444, 451, 499, 501, 507, 508, 510, 561, 613
- Peripheral blood lymphocytes 129, 210, 261, 444
- Peripheral blood stem cell collection 66
- Peripheral blood stem cell transplantation 267, 501
- Peripheral blood stem cells 200, 507, 510
- Peripheral T-cell lymphoma 47, 100, 102, 124, 125, 309, 322, 323, 362, 512, 520, 611
- PET scanning 19, 286, 366, 368
- Pharmacokinetics 96, 255, 399, 585, 586
- Phase I study 15, 33, 38, 45, 53, 54, 55, 60, 61, 65, 67, 71, 89, 96, 97, 98, 100, 101, 103, 105, 106, 108, 110, 111, 115, 116, 118, 129, 149, 179, 198, 212, 215, 217, 228, 229, 250, 251, 252, 256, 265, 298, 328, 329, 332, 333, 334, 337, 380, 386, 393, 396, 401, 402, 404, 405, 425, 426, 476, 485, 487, 489, 491, 498, 501, 505, 509, 520, 522, 570, 572, 573, 579, 580, 582, 583, 587, 589, 591, 607
- Phase I/II study 96, 101, 106, 115, 332, 396, 509, 580, 583, 589, 591
- Phase II study 15, 33, 45, 53, 54, 55, 60, 61, 65, 67, 71, 89, 97, 98, 100, 101, 103, 108, 110, 116, 118, 149, 179, 198, 212, 217, 228, 229, 250, 251, 252, 256, 265, 298, 329, 334, 337, 380, 386, 396, 401, 402, 404, 405, 425, 426, 476, 485, 487, 489, 491, 498, 501, 505, 520, 522, 570, 572, 573, 579, 580, 582, 587, 591, 607
- Phase II/III study 149
- Phase III study 33, 45, 53, 60, 61, 89, 108, 179, 198, 229, 250, 252, 265, 487, 498, 501, 580
- Philadelphia chromosome 84
- Platelet count 201, 220, 333, 379, 453, 578, 584, 593
- Platelet transfusion 573
- PMBL 26, 186
- Point mutation 21, 140, 559
- Polymerase chain reaction 17, 30, 39, 40, 42, 46, 83, 122, 127, 128, 137, 140, 144, 145, 146, 148, 149, 153, 160, 166, 168, 170, 177, 183, 187, 195, 218, 234, 240, 247, 248, 251, 303, 307, 308, 309, 311, 345, 347, 351, 353, 354, 356, 363, 364, 382, 383, 385, 391, 394, 404, 409, 410, 411, 421, 423, 437, 450, 451, 463, 464, 508, 528, 555, 581, 590, 609, 615
- Poor outcome 72, 77, 108, 124, 214, 304, 322, 362, 495, 503, 551
- Population-based 73, 271, 341, 448
- Positron emission tomography 11, 19, 73, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 326, 332, 344, 366, 367, 368, 370, 371, 372, 373, 399, 497, 532, 542, 568, 593
- Post-transplant lymphoproliferative disorders 254
- Post-transplant lymphoma 139
- Preclinical toxicology 589
- Predictive factors 516
- Prednisolone 60, 226, 301, 487, 517, 584
- Prednisone 12, 76, 107, 197, 203, 210, 224, 228, 229, 246, 249, 269, 304, 388, 454, 475, 478, 481, 491, 495, 501, 507, 541, 547, 582, 600
- Pregnancy 279
- Primary bone lymphoma 432
- Primary central nervous system lymphoma 102, 296, 443
- Primary cutaneous B-cell lymphoma 317
- Primary effusion lymphoma 138, 307
- Primary extranodal non-Hodgkin's lymphoma 416
- Primary mediastinal B-cell lymphoma 186
- Primary mediastinal large B-cell lymphoma 73, 86, 185, 433
- Primary mediastinal lymphoma 399, 468
- Prognostic factors 1, 14, 15, 32, 36, 38, 63, 66, 72, 76, 78, 88, 92, 93, 119, 121, 130, 151, 203, 205, 208, 209, 212, 213, 221, 222, 223, 232, 249, 263, 264, 267, 270, 280, 281, 288, 296, 317, 319, 326, 350, 372, 380, 409, 414, 416, 438, 440, 461, 467, 469, 480, 508, 511, 513, 519, 530, 531, 533, 540, 550, 561, 563, 564, 565, 601, 613
- Prognostic index 202, 237, 241, 288
- Prognostic marker 36, 109, 196, 458, 462, 464, 561, 564, 565, 613
- Prognostic model 202, 241, 462
- Prognostic value 36, 63, 66, 76, 92, 119, 130, 222, 280, 281, 296, 326, 409, 508, 530, 531, 533, 540, 565
- Progression-free survival 39, 53, 58, 62, 63, 65, 73, 76, 204, 215, 231, 241, 252, 253, 264, 265, 274, 280, 290, 294, 300, 331, 340, 350, 388, 398, 442, 452, 566
- Proinflammatory cytokines 575
- Proliferation 4, 37, 52, 76, 108, 110, 122, 125, 128, 141, 149, 151, 158, 163, 165, 174, 176, 196, 340, 362, 411, 446, 457, 576, 581, 588, 590, 592, 606, 607, 611
- Proliferation index 76, 196
- Proliferative index 87, 196
- Prolonged response 331
- Proteasome inhibition 149
- Purine analogs 39, 400, 401, 571, 572
- Q**
- 3q27 region 147, 353
- 11q deletions 169
- Quality of life 32, 38, 443, 487, 536, 547, 570, 604, 605
- Quantitative PCR 404
- R**
- Radiation dose 59, 215, 440, 594
- Radioimmunotherapy 53, 64, 334, 402
- Radiotherapy 57, 58, 59, 73, 88, 203, 217, 223, 242, 243, 244, 261, 264, 265, 272, 273, 274, 275, 278, 279, 282, 284, 298, 301, 302, 315, 316, 326, 329, 365, 373, 376, 383, 385, 420, 425, 426, 431, 432, 433, 436, 437, 438, 440, 462, 465, 468, 469, 472, 474, 480, 495, 497, 499, 501, 504, 529, 531, 532, 537, 538, 540, 541, 543, 547, 556, 577, 578, 600, 601
- Rapamycin 23, 95, 101, 588
- Ras 8
- Rasburicase 96, 595
- REAL classification 102
- Real-time quantitative PCR 349
- Recombinant idiotype 118
- Reduced-intensity conditioning 177
- Reed–Sternberg cells 156, 161, 262, 529
- Relapsed aggressive lymphoma 490
- Relapsed anaplastic large cell lymphoma 90
- Relapsed follicular lymphoma 17, 252, 456
- Relapsed lymphoma 510
- Relapsed/refractory lymphoma 97
- Remission 12, 15, 17, 19, 39, 41, 42, 43, 53, 54, 61, 62, 64, 71, 79, 88, 95, 96, 112, 118, 162, 177, 191, 193, 194, 198, 199, 204, 208, 216, 217, 222, 244, 251, 252, 253, 254, 261, 266, 267, 268, 279, 282, 289, 299, 301, 316, 333, 338, 343, 350, 368, 373, 377, 380, 388, 389, 390, 394, 398, 399, 401, 402, 404, 406, 407, 408, 414, 415, 416, 420, 421, 423, 424, 425, 433, 435, 437, 438, 440, 449, 450, 451, 462, 464, 468, 477, 489, 492, 493, 495, 496, 497, 499, 501, 502, 504, 510, 532, 536, 539, 541, 543, 545, 550, 551, 552, 555, 572, 578, 582, 584, 586, 591, 593, 600, 601, 603, 610
- Response evaluation 283, 323
- Response rates 19, 40, 53, 55, 65, 101, 104, 149, 198, 200, 226, 228, 251, 252, 265, 270, 273, 294, 334, 355, 388, 395, 402, 406, 412, 456, 486, 569, 619
- Retrospective analysis 34, 202, 204, 241, 266, 268, 279, 483, 491, 544, 603
- R-HCVAD 197
- Risk assessment 273
- Risk factors 4, 32, 41, 57, 151, 202, 204, 212, 236, 241, 269, 270, 283, 381, 459, 506, 519, 533
- Rituximab 14, 17, 38, 39, 44, 45, 49, 53, 55, 60, 61, 65, 67, 79, 101, 103, 104, 105, 106, 107, 108, 109, 114, 115, 140, 180, 183, 192, 198, 200, 208, 210, 215, 218, 220, 224, 225, 227, 228, 247, 249, 250, 251, 252, 253, 254, 255, 256, 287, 294, 318, 325, 329, 332, 334, 336, 340, 344, 355, 376, 377, 380, 383, 389, 390, 394, 397, 399, 402, 403, 404, 407, 408, 410, 420, 425, 427, 428, 449, 450, 454, 456, 466, 472, 473, 475, 476, 477, 478, 479, 480, 481, 482, 483, 485, 486, 489, 490, 491, 492, 494, 495, 496, 500, 502, 505, 506, 507, 509, 545, 570, 571, 572, 573, 585, 587, 591, 592, 599, 614, 619
- S**
- Safety profile 105, 111, 114, 386
- Salvage therapy 1, 39, 90, 211, 214, 220, 236, 252, 266, 274, 275, 299, 430, 491, 493, 503
- Sarcoma 5, 273, 307, 324
- sCD30 312
- Scotland 190, 376, 448, 537
- Screening 18, 20, 32, 120, 135, 173, 273, 278, 311, 356, 357
- SCT 12, 19, 33, 42, 43, 64, 90, 112, 177, 211, 216, 218, 220, 285, 325, 369, 453, 455
- Second malignancies 32, 57, 274, 597
- Sequential chemotherapy 267
- SEREX analysis 170
- Serum levels 105, 255, 339, 472, 484, 554, 566, 572, 575, 598
- Signal transduction pathways 111, 117, 172, 313, 576
- Sinuses 414, 415
- Skin involvement 100, 324
- Small lymphocytic lymphoma 59, 94, 99, 256, 380, 397, 474
- Solid malignancies 1
- Solid tumors 1, 18, 274, 362, 522, 543, 577, 610
- Soluble CD23 563
- Somatic mutation 30, 37, 52, 361, 560
- Spleen 49, 183, 207, 241, 316, 319, 410, 412, 429, 535, 616
- Splenectomy 294
- Splenic marginal zone lymphoma 50, 411
- Staging 80, 83, 89, 94, 102, 222, 259, 286, 289, 366, 367, 371, 372, 390, 424, 445, 484, 488, 513, 543, 547, 557
- Standard P-VABEC regimen 229
- Stanford V regimen 284
- STAT3 162, 576
- Stem cell transplantation 1, 12, 199, 201, 220, 253, 402, 451, 462, 492, 499, 504
- Stem cells 1, 12, 19, 20, 64, 111, 199, 201, 212, 217, 219, 220, 240, 246, 253, 254, 267, 285, 298, 331, 333, 369, 383, 388, 402, 403, 451, 453, 454, 455, 462, 470, 472, 490, 492, 493, 498, 499, 501, 502, 504, 508, 546, 578, 593, 597
- Sterility 279

Stomach 83, 191, 192, 193, 324, 415, 416, 424, 425, 428, 474  
 Suberoylanilide hydroxamic acid 55, 101  
 Supportive care 63  
 Survival advantage 15, 60, 73, 190, 470, 569  
 Survival trends 260

## T

Tamoxifen 32  
 Taxol 494  
 T-cell 12, 16, 19, 27, 30, 36, 47, 69, 72, 79, 81, 89, 113, 123, 125, 128, 129, 131, 136, 143, 144, 156, 211, 238, 254, 259, 304, 308, 309, 310, 319, 323, 342, 344, 347, 392, 393, 415, 422, 474, 487, 511, 512, 513, 514, 517, 521, 530, 572, 587, 602, 609, 610, 611  
 T-cell clonality 254, 308  
 T-cell lymphoma 47, 72, 123, 131, 144, 211, 309, 310, 323, 347, 415, 422, 474, 512, 517, 521, 572, 587, 609, 610  
 Temozolomide 442, 522  
 Testicular lymphoma 468  
 Thalidomide 11, 12, 13, 55, 101, 340, 355, 553, 579, 584  
 419, 531  
 Therapeutic vaccination 580  
 Thiotepa 298  
 Thrombocytopenia 41, 65, 95, 96, 97, 98, 103, 179, 244, 300, 319, 321, 323, 333, 335, 386, 389, 390, 391, 400, 401, 403, 405, 467, 470, 475, 479, 484, 486, 488, 490, 492, 496, 515, 550, 570, 584, 587, 593, 594

Thymidine kinase 38  
 Time of relapse 233  
 Topoisomerase II- $\alpha$  616  
 Topotecan 220, 299, 494  
 Tositumomab 63, 64, 255, 256, 453, 594  
 Total therapy 283  
 Transcription factors 27, 121, 126, 141, 161, 163, 187, 314, 351, 457  
 Transplantation 6, 12, 14, 19, 38, 153, 211, 218, 246, 254, 263, 290, 344, 368, 369, 392, 454, 493, 500, 502, 504, 551, 578, 597  
 Transplant-related mortality 404  
 Treatment choice 537  
 Treatment modality 301, 334, 380  
 Treatment outcome 43, 86, 192, 268, 280, 281, 315, 517, 603  
 Treatment relapse 468  
 Tumor antigen 132  
 Tumor burden 115, 255, 379, 456, 566  
 Tumor markers 383  
 Tumor necrosis factor 31, 110, 127  
 Tumor necrosis factor- $\alpha$  27, 31, 97, 110, 127, 314, 330, 352, 575  
 Tumor progression 8, 235, 415, 416, 442, 512, 592  
 Tumor size 204, 502  
 Tumor suppressor genes 25, 56, 359, 511  
 Tyrosine kinase 13, 36, 37, 125, 164, 172, 460, 564

## U

Uric acid 595

## V

Vaccination 17, 18, 118, 132, 133, 329, 346, 580, 602, 615  
 Vascular endothelial growth factor 524, 566  
 Vascular endothelial growth factor (VEGF) 13, 331, 488, 524, 566, 575, 576  
 VCAM-1 566  
 VH genes 146, 175, 357  
 Vinblastine 516, 518, 544, 548, 553, 600  
 Vincristine 70, 76, 90, 210, 217, 224, 226, 228, 249, 267, 301, 338, 388, 441, 454, 467, 470, 475, 478, 481, 485, 486, 487, 500, 505, 507, 517, 541, 547, 582, 587, 600  
 Vindesine 90, 203  
 Vinorelbine 304, 491, 495  
 VP16, 203, 214, 400, 404, 470, 499, 503, 548

## W

Waldenström's macroglobulinemia 50, 101  
 WHO classification 1, 2, 47, 50, 73, 82, 102, 205, 241, 375, 376, 377, 379, 385, 429, 554  
 WM 50, 97, 98, 168, 257, 258, 409, 555, 568, 572, 608

## Z

Zevalin 201, 215, 333, 453, 456, 509, 591, 592